G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

The authors stated that the oral tablets had a distinguishing feature that allowed for “similar or better efficacy and similar tolerability” compared with most injectable GLP-1 receptor agonists.

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon ... a once-daily tablet, combines OPKO's ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

OPKO Health (OPK) and Entera Bio (ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...